Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
4 hedge funds and large institutions have $336M invested in Sinovac Biotech, Ltd in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
20% less capital invested
Capital invested by funds: $418M → $336M (-$82.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less funds holding
Funds holding: 9 → 4 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$76.3M |
| 2 |
HI
Horizon Investments
Charlotte,
North Carolina
|
-$336 |
SVA Hedge Fund Activity: Q4 2024 in Review
4 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2024, worth a combined $336M — down 20% from $418M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SVA and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vivo Capital, exiting entirely with an estimated $76.3M sold.
- 4 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2024, down from 9 in Q3 2024.
- Funds reported $336M of Sinovac Biotech, Ltd stock for Q4 2024, down 20% quarter-over-quarter.
- 0 funds opened new Sinovac Biotech, Ltd positions in Q4 2024 and 5 closed out, a net change of -5 holders.
- The largest Sinovac Biotech, Ltd seller in Q4 2024 was Vivo Capital, an estimated $76.3M sold.
Based on aggregated 13F filings for Q4 2024.